1921
Volume 77, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Leprosy affects skin and peripheral nerves, and acute inflammatory type 1 reactions (reversal reaction) can cause neurologic impairment and disabilities. Single skin lesion paucibacillary leprosy volunteers ( = 135) recruited in three Brazilian endemic regions, treated with single-dose rifampin, ofloxacin, and minocycline (ROM), were monitored for 3 years. Poor outcome was defined as type 1 reactions with or without neuritis. IgM anti-phenolic glycolipid I, histopathology, Mitsuda test, and DNA polymerase chain reaction (ML-PCR) were performed at baseline. χ test, Kaplan-Meir curves, and Cox proportional hazards were applied. The majority of volunteers were adults with a mean age of 30.5 ± 15.4 years; 44.4% were ML-PCR positive. During follow-up, 14.8% of the patients had a poor clinical outcome, classified as a type 1 reaction. Older age (≥40 years), ML-PCR positivity, and lesion size > 5cm were associated with increased risk. In multivariate analysis, age (≥40 years) and ML-PCR positivity remained baseline predictors of type 1 reaction among monolesion leprosy patients.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2007.77.829
2007-11-01
2017-11-22
Loading full text...

Full text loading...

/deliver/fulltext/14761645/77/5/0770829.html?itemId=/content/journals/10.4269/ajtmh.2007.77.829&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2007. Leprosy: global situation. Available at www.who.int/lep/situation. Acessed January 2, 2007.
  2. Modlin RL, Melancon-Kaplan J, Young SM, Pirmez C, Kino H, Convit J, Rea TH, Bloom BR, 1988. Learning from lesions: patterns of tissue inflammation in leprosy. Proc Natl Acad Sci USA 85 : 1213–1217.
  3. Yamamura M, Uyemura K, Deans RJ, Weinberg K, Rea TH, Bloom BR, Modlin RL, 1991. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 254 : 277–279.
  4. Ridley D, Jopling W, 1966. Classification of leprosy according to immunity; a five-group system. Int J Lepr Other Mycobact Dis 31 : 255–273.
  5. Single-lesion Multicentre Trial Group, 1997. Efficacy of single dose multidrug therapy for the treatment of single-lesion paucibacillary leprosy. Single-lesion Multicentre Trial Group. Indian J Lepr 69 : 121–129.
  6. Aseffa A, Brennan P, Dockrell H, Gillis T, Hussain R, Oskam L, Richardus JH, 2005. Report on the first meeting of the IDEAL (Initiative for Diagnostic and Epidemiological Assays for Leprosy) consortium held at Armauer Hansen Research Institute, ALERT, Addis Ababa, Ethiopia on 24–27 October 2004. Lepr Rev 76 : 147–159.
  7. Costa M, Cavalcanti FF, Martelli CMT, Stefani MMA, Macieira J, Gomes MK, Schettini A, Rebello P, Pignataro P, Ueda E, Narahashi K, Scollard D, 2000. Distinct histopatological patterns of single skin lesion leprosy patients treated with single dose therapy (ROM) in the Brazilian multicentric study. Int J Lepr Other Mycobact Dis 169 : 177–186.
  8. Martelli C, Stefani M, Gomes M, Rebello P, Peninni S, Narahashi K, Maroclo A, Costa M, Silva S, Sacchetim S, Nery J, Salles A, Gillis T, Krahenbuhl J, Andrade A, 2000. Single lesion pauci-bacillary leprosy: baseline profile of the Brazilian multicenter cohort study. Int J Lepr Other Mycobact Dis 68 : 247–257.
  9. Oskam L, Slim E, Buhrer-Sekula S, 2003. Serology: recent developments, strengths, limitations and prospects: a state of the art overview. Lepr Rev 74 : 196–205.
  10. Ponnighaus J, Fine P, 1988. Leprosy in Malawi. 1. Sensitivity and specificity of the diagnosis and the search for risk factors for leprosy. Trans R Soc Trop Med Hyg 82 : 803–809.
  11. Donoghue HD, Holton J, Spigelman M, 2001. PCR primers that can detect low levels of Mycobacterium leprae DNA. J Med Microbiol 50 : 177–182.
  12. Stefani MM, Martelli CM, Gillis TP, Krahenbuhl JL, 2003. In situ type 1 cytokine gene expression and mechanisms associated with early leprosy progression. J Infect Dis 188 : 1024–1031.
  13. Williams DL, Gillis TP, Booth RJ, Looker D, Watson JD, 1990. The use of a specific DNA probe and polymerase chain reaction for the detection of Mycobacterium leprae. J Infect Dis 162 : 193–200.
  14. Stefani M, Martelli C, Morais-Neto O, Martelli P, Costa M, Andrade A, 1998. Assessment of anti-PGL 1 as a prognostic marker of leprosy reaction. Int J Lepr Other Mycobact Dis 66 : 356–364.
  15. Ranque B, Nguyen VT, Vu HT, Nguyen TH, Nguyen NB, Pham XK, Schurr E, Abel L, Alcais A, 2007. Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy. Clin Infect Dis 44 : 33–40.
  16. Scollard D, Gillis T, Williams D, 1998. Polymerase Chain Reaction Assay for the Detection and Identification of Mycobacterium leprae in Patients in the United States. Am J Clin Pathol 109 : 640–646.
  17. Roche PW, Theuvenet WJ, Britton WJ, 1991. Risk factors for type-1 reactions in borderline leprosy patients. Lancet 338 : 654–657.
  18. Britton WJ, 1998. The management of leprosy reversal reactions. Lepr Rev 69 : 225–234.
  19. Lienhardt C, Fine PE, 1994. Type 1 reaction, neuritis and disability in leprosy. What is the current epidemiological situation? Lepr Rev 65 : 9–33.
  20. Lockwood D, 2002. Leprosy elimination—a virtual phenomenon or a reality? BMJ 324 : 1516–1518.
  21. Rose P, Waters MF, 1991. Reversal reactions in leprosy and their management. Lepr Rev 62 : 113–121.
  22. de Rijk AJ, Gabre S, Byass P, Berhanu T, 1994. Field evaluation of WHO-MDT of fixed duration, at ALERT, Ethiopia: the AMFES project–II. Reaction and neuritis during and after MDT in PB and MB leprosy patients. Lepr Rev 65 : 320–332.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2007.77.829
Loading
/content/journals/10.4269/ajtmh.2007.77.829
Loading

Data & Media loading...

  • Received : 28 Feb 2007
  • Accepted : 23 Aug 2007

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error